EyePoint Pharmaceuticals (EYPT) News Today $23.11 -0.45 (-1.91%) (As of 12/29/2023 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Down 32.2% in Decembermarketbeat.com - December 31 at 12:20 AMVontobel Holding Ltd. Has $1.41 Million Stock Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)marketbeat.com - December 25 at 4:21 AMEyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - December 20 at 10:32 AMEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5% After Insider Sellingmarketbeat.com - December 18 at 2:56 PMWhat EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling Youfinance.yahoo.com - December 18 at 10:04 AMEyePoint Pharmaceuticals (EYPT) Price Target Increased by 37.87% to 42.50msn.com - December 17 at 2:49 AMInsider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Sells 1,458 Shares of Stockmarketbeat.com - December 15 at 7:03 PMCantor Fitzgerald Comments on EyePoint Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:EYPT)marketbeat.com - December 14 at 6:48 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%finance.yahoo.com - December 13 at 10:35 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) to Post FY2023 Earnings of ($2.27) Per Share, Capital One Financial Forecastsmarketbeat.com - December 13 at 7:29 AMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Purchases $9,999,995.00 in Stockmarketbeat.com - December 12 at 6:36 PMCapital One Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Overweight Recommendationmsn.com - December 11 at 7:34 PMEyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?finance.yahoo.com - December 11 at 2:34 PMEyePoint Pharmaceuticals (NASDAQ:EYPT) Coverage Initiated by Analysts at Capital One Financialmarketbeat.com - December 11 at 10:21 AMInstitutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43% ownershipfinance.yahoo.com - December 11 at 9:33 AMEyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Sharesfinance.yahoo.com - December 8 at 7:28 PMWhat Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'finance.yahoo.com - December 8 at 2:28 PMWall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Tradefinance.yahoo.com - December 8 at 2:28 PMThis Tech Stock Is 'Too Expensive,' Cramer Says: 'Wait For A Pullback'benzinga.com - December 8 at 9:28 AMInsider Trading: EyePoint’s (NASDAQ:EYPT) Insider Makes an Enormous Purchasemsn.com - December 7 at 11:12 PMInsider Sell Alert: Chief Corp Dev. & Strat.finance.yahoo.com - December 7 at 6:11 PMInsider Sell Alert: Chief Corp Dev. & Strat. ...finance.yahoo.com - December 7 at 6:11 PMEyePoint Pharmaceuticals Stock (NASDAQ:EYPT) Dividends: History, Yield and Datesbenzinga.com - December 6 at 7:38 PMBuy Rating Affirmed for EyePoint Pharmaceuticals Following EYP-1901’s Promising Trial Outcomesmarkets.businessinsider.com - December 6 at 9:38 AMEyePoint Pharmaceuticals prices upsized $200 million stock offeringmsn.com - December 6 at 9:38 AMEyePoint Pharmaceuticals Announces Pricing of Upsized Public Offeringfinance.yahoo.com - December 5 at 11:21 PMEyePoint data suggest time-released drug may help patients with macular degenerationmsn.com - December 5 at 1:20 PMEyePoint (EYPT) Surges 178% on Upbeat Phase II Eye Disease Datafinance.yahoo.com - December 5 at 1:20 PMEyePoint Pharmaceuticals Soaring On Wet AMD Study Results: Durasert Looks Real Dealseekingalpha.com - December 5 at 10:30 AMCrude Oil Falls Over 1%; EyePoint Pharmaceuticals Shares Spike Highermsn.com - December 5 at 8:19 AMAfter-hours movers: GitLab surges on earnings, EyePoint adds to intra-day gainsinvesting.com - December 4 at 7:15 PMEyePoint Pharmaceuticals’ stock soars 200% after company announces positive data for macular degeneration treatmentmsn.com - December 4 at 7:15 PMWatertown biotech shares surge nearly 200% on new drug databizjournals.com - December 4 at 2:15 PMEyePoint Pharmaceuticals’ stock soars 212% after company announces positive data for macular degeneration treatmentmsn.com - December 4 at 2:15 PMEyePoint Pharmaceuticals Phase 2 Macular Degeneration Treatment Trial Shows Positive Resultsmarketwatch.com - December 4 at 9:14 AMEyePoint's Phase 2 DAVIO 2 Trial Of EYP-1901 Achieves Primary, Secondary Endpoints In Wet AMDmarkets.businessinsider.com - December 4 at 9:14 AMWhy Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?markets.businessinsider.com - December 4 at 9:14 AMEyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD Achieving All Primary and Secondary Endpointsfinance.yahoo.com - December 4 at 9:14 AMmarketbeat.com - December 4 at 6:57 AMShorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gainseekingalpha.com - November 30 at 4:39 PMDoes EyePoint Pharmaceuticals (EYPT) Have the Potential to Rally 336.07% as Wall Street Analysts Expect?finance.yahoo.com - November 21 at 1:39 PMEyePoint Pharmaceuticals Inc EYPTmorningstar.com - November 9 at 9:16 AMCountdown To Clarity: EyePoint's December Data Deliveryseekingalpha.com - November 8 at 8:04 AMNeed To Know: Analysts Are Much More Bullish On EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Revenuesfinance.yahoo.com - November 3 at 7:25 AMMizuho Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy Recommendationmsn.com - November 3 at 1:54 AMExpert Ratings for EyePoint Pharmaceuticalsmarkets.businessinsider.com - November 2 at 8:53 PMEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 2 at 8:53 PMWhy Is Vision Disorder-Focused EyePoint Pharmaceuticals Stock Trading Higher Today?msn.com - November 1 at 6:04 PMEyePoint Pharmaceuticals beats Q3 top and bottom line estimatesmsn.com - November 1 at 1:04 PMEyePoint Pharmaceuticals Inc (EYPT) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 1 at 1:04 PM Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼1.610.84▲Average Medical News Sentiment EYPT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼42▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: QTRX News CTKB News NAUT News HBIO News AXDX News BNGO News OLK News AMLX News ADMA News PRME News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:EYPT) was last updated on 12/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.